An observational study in Obesity, Diabetes Mellitus and Metabolic Syndrome, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Medical University of Bialystok · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Obesity by Medical University of Bialystok — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Medical University of Bialystok.
Among the 16 studies in Obesity by Medical University of Bialystok, this one is the only one that started in 2015, is one of 8 observational ones, and was the 3rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →4 of the 16 studies in Obesity by Medical University of Bialystok are open now, in 1 country. Recruiting first, the newest first:
Medical University of Bialystok · Sites in Poland
Ages 18–65 · Healthy volunteers
Medical University of Bialystok · Sites in Poland
Healthy volunteers
Medical University of Bialystok · Sites in Poland
Ages 20–80
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 101 across the 8 interventional studies, 118 across the 8 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.
1 of the studies in Obesity by Medical University of Bialystok that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634591Medical University of BialystokThe Bialystok Bariatric Surgery Study | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Obesity by Medical University of Bialystok, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Bialystok Bariatric Surgery Study (BBSS) is a prospective observational cohort study of patients undergoing bariatric surgery at the First Clinical Department of General and Endocrine Surgery at the Medical University of Bialystok. The BBSS consists of a battery of baseline tests established one month prior to the surgery and repeated at one, three, six, twelve and twenty four-month follow-up clinical visits.
In Bialystok Bariatric Surgery Study (BBSS), we observe a cohort study of patients who undergo bariatric surgery in the First Clinical Department of General and Endocrine Surgery of the Medical University of Bialystok. This center performs several types of bariatric surgery including Roux-en-Y gastric bypass (RYGB), adjustable gastric banding (AGB), and sleeve gastrectomy (SG) in patients referred to the clinic by general practitioners and endocrinologists and who were qualified for the surgery according to the clinical physicians. Only patients who agreed to participate in the research project, specified in detail during written and oral patients consent, are included. Moreover, the study population consists of the group of obese patients who do not undergo the surgery and are followed-up without the surgical intervention and the non-obese control group of patients without obesity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Non-obese control group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with morbid obesity, treated with the bariatric surgery
Procedure: Bariatric surgery
Patients with morbid obesity, not treated with the bariatric surgery
Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
Also known as: Metabolic surgery
Weight loss
Changes in total body weight under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Lean body mass
Changes in total lean body mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Fat mass
Changes in total fat mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Visceral adipose tissue mass
Changes in visceral adipose tissue mass under the surgery, measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Fasting glucose
Changes in fasting glucose concentration under the surgery, measured in plasma using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Triglycerides (TG)
Changes in serum triglycerides concentration under the surgery, measured using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
High-density lipoprotein cholesterol (HDL)
Changes in serum High-density lipoprotein cholesterol (HDL) concentration under the surgery, measured using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Low-density lipoprotein cholesterol (LDL)
Changes in serum Low-density lipoprotein cholesterol (LDL) concentration under the surgery, measured using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Total cholesterol
Changes in serum total cholesterol concentration under the surgery, measured using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Fasting insulin
Changes in fasting insulin concentration under the surgery, measured by the immunoradiometric assay (IRMA)
Time frame: 1, 3, 6, 12 and 24 months after the surgery
2-hour glucose
Changes in glucose concentration at 2-hour of the oral glucose tolerance test under the surgery, measured in plasma using the colorimetric method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Haemoglobin A1c (HbA1c)
Changes in Haemoglobin A1c under the surgery, measured by the high-performance liquid chromatography (HPLC) method
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Homeostatic model assessment for insulin resistance (HOMA-IR)
Changes in Homeostatic model assessment for insulin resistance under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Homeostatic model assessment of beta cell function (HOMA-beta)
Changes in Homeostatic model assessment of beta cell function under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Changes in glucose and insulin concentrations during the oral glucose tolerance test (OGTT)
Changes in concentrations of glucose and insulin during the oral glucose tolerance test, under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Changes in glucose and insulin concentrations during the mixed meal tolerance test (MMTT)
Changes in concentrations of glucose and insulin during the mixed meal tolerance test, under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Changes in GI hormones concentrations during the oral glucose tolerance test (OGTT)
Changes in concentrations of gastrointestinal hormones during the oral glucose tolerance test, under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Changes in GI hormones concentrations during the mixed meal tolerance test (MMTT)
Changes in concentrations of gastrointestinal hormones during the mixed meal tolerance test, under the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Plasma metabolome
Changes in plasma metabolites concentrations measured using untargeted metabolomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Plasma proteome
Changes in plasma proteins concentrations measured using targeted and untargeted proteomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Urine metabolome
Changes in urine metabolites concentrations measured using untargeted metabolomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Skeletal muscle transcriptome
Changes in skeletal muscle gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Liver transcriptome
Changes in liver gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Adipose tissue transcriptome
Changes in adipose tissue gene and small RNA expressions measured using untargeted transcriptomics, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Circulating microRNA
Changes in circulating microRNAs expression, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Liver methylome
Changes in liver DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Skeletal muscle methylome
Changes in skeletal muscle DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Adipose tissue methylome
Changes in adipose tissue DNA methylations measured using Reduced representation bisulfite sequencing (RRBS) method, in response to the surgery
Time frame: 1, 3, 6, 12 and 24 months after the surgery
Started Sep 2015 (actual). Primary completion is estimated for Dec 2026, 135 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 135 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Bialystok